News | May 25, 2021
Bal Pharma launches BALflu, Favipiravir formulation in India
BALflu is approved by DCGI for emergency use for the treatment of COVID-19
BALflu is approved by DCGI for emergency use for the treatment of COVID-19
The drug accumulates in the virus infected cells and prevents virus growth by stopping viral synthesis and energy production
Indian government is expecting pharmaceutical industry to fetch incremental sales worth Rs. 294,000 crore and exports up to Rs. 196,000 crore by FY 2027-28
ICICI Securities expects Hemmo to grow its revenue at a CAGR of 30.0% over FY21E-FY23E
This acquisition marks PPS’ foray into the development and manufacturing of peptide APIs
174 applications were received for 23 eligible products under Target Segment IV - Other Chemical Synthesis Based KSMs/ Drug Intermediates/APIs.
The company received approval for 2-Methyl-5Nitro-Imidazole (2-MNI) with a committed production capacity of 4,000 MT per annum.
Tiger can no longer make an important biotin intermediate using a DSM patented process.
The company has concluded our acquisition of Richcore Lifesciences on 20th Jan 2021.
Subscribe To Our Newsletter & Stay Updated
